Recent Advances in the Acute Management of Migraine and Cluster Headaches

Overview

Journal J Gen Intern Med

Publisher Springer

Specialty General Medicine

Date 1994 Jun 1

PMID 8078000

Authors

K L Kumar

Affiliations

Soon will be listed here.

Abstract

I have discussed the pharmacokinetics, efficacies, and side effects of the various nonnarcotic drugs available for the treatment of patients who have headache. Sumatriptan, the newest one, is expensive but may be cost-effective for those who have failed traditional migraine treatment, who visit the ER frequently, who have potential for drug abuse, or who have to miss time from school or work due to the headache. Studies are in progress to compare sumatriptan with other available drugs such as DHE-45 and to determine its possible role in the prophylaxis of migraine. A new 5-HT1D receptor agonist with more efficacy and fewer side effects may be developed in the future. When sumatriptan and DHE-45 are contraindicated due to hypertension or coronary artery disease, other drugs such as metoclopramide, ketorolac, and butorphanol can be used as alternatives.

References

Elenbaas R, Iacono C, Koellner K, Pribble J, Gratton M, Racz G . Dose effectiveness and safety of butorphanol in acute migraine headache. Pharmacotherapy. 1991; 11(1):56-63. View

. A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group. Eur Neurol. 1991; 31(5):314-22. DOI: 10.1159/000116759. View

. A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group. Eur Neurol. 1992; 32(3):177-84. DOI: 10.1159/000116818. View

Turkewitz L, Casaly J, Dawson G, Wirth O, Hurst R, Gillette P . Self-administration of parenteral ketorolac tromethamine for head pain. Headache. 1992; 32(9):452-4. DOI: 10.1111/j.1526-4610.1992.hed3209452.x. View

Curtin T, Brooks A, Roberts J . Cardiorespiratory distress after sumatriptan given by injection. BMJ. 1992; 305(6855):713-4; author reply 714. PMC: 1882941. DOI: 10.1136/bmj.305.6855.713-d. View

. Treatment of acute cluster headache with sumatriptan. N Engl J Med. 1991; 325(5):322-6. DOI: 10.1056/NEJM199108013250505. View

Ottervanger J, Paalman H, Boxma G, Stricker B . Transmural myocardial infarction with sumatriptan. Lancet. 1993; 341(8849):861-2. DOI: 10.1016/0140-6736(93)93064-8. View

KOFFER H, Hildebrand 3rd J, CONNELL M . Potential for nonnarcotic analgesics to save personnel costs associated with controlling injectable morphine and meperidine. Am J Hosp Pharm. 1990; 47(5):1084-8. View

RASKIN N . Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology. 1986; 36(7):995-7. DOI: 10.1212/wnl.36.7.995. View

10.

Fowler P, Lacey L, Thomas M, Keene O, Tanner R, Baber N . The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol. 1991; 31(5):291-4. DOI: 10.1159/000116756. View

11.

Ekbom K, Monstad I, PRUSINSKI A, Cole J, Pilgrim A, Noronha D . Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparison study. The Sumatriptan Cluster Headache Study Group. Acta Neurol Scand. 1993; 88(1):63-9. DOI: 10.1111/j.1600-0404.1993.tb04189.x. View

12.

Inman W, Kubota K . Cardiorespiratory distress after sumatriptan given by injection. BMJ. 1992; 305(6855):714. PMC: 1882911. DOI: 10.1136/bmj.305.6855.714. View

13.

Mathew N . Transformed migraine. Cephalalgia. 1993; 13 Suppl 12:78-83. DOI: 10.1177/0333102493013S1217. View

14.

Willett F, Curzen N, Adams J, Armitage M . Coronary vasospasm induced by subcutaneous sumatriptan. BMJ. 1992; 304(6839):1415. PMC: 1882171. DOI: 10.1136/bmj.304.6839.1415. View

15.

Spindler J, Mehlisch D, Brown C . Intramuscular ketorolac and morphine in the treatment of moderate to severe pain after major surgery. Pharmacotherapy. 1990; 10(6 ( Pt 2)):51S-58S. View

16.

Brown E, Endersby C, Smith R, Talbot J . The safety and tolerability of sumatriptan: an overview. Eur Neurol. 1991; 31(5):339-44. DOI: 10.1159/000116762. View

17.

Mathew N, Dexter J, Couch J, Flamenbaum W, Goldstein J, Rapoport A . Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol. 1992; 49(12):1271-6. DOI: 10.1001/archneur.1992.00530360073020. View

18.

Geppetti P, Fusco B, Marabini S, Maggi C, Fanciullacci M, SICUTERI F . Secretion, pain and sneezing induced by the application of capsaicin to the nasal mucosa in man. Br J Pharmacol. 1988; 93(3):509-14. PMC: 1853845. DOI: 10.1111/j.1476-5381.1988.tb10305.x. View

19.

Tulunay F, Karan O, Aydin N, Culcuoglu A, Guvener A . Dihydroergotamine nasal spray during migraine attacks. A double-blind crossover study with placebo. Cephalalgia. 1987; 7(2):131-3. DOI: 10.1046/j.1468-2982.1987.0702131.x. View

20.

Osterhaus J, Gutterman D, Plachetka J . Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics. 1992; 2(1):67-76. DOI: 10.2165/00019053-199202010-00008. View